# REVIEW

# Cervical Cancer in the Asian Pacific - Epidemiology, Screening and Treatment

**Malcolm A Moore[1], Kazuo Tajima[2]**

## Abstract

   Squamous cell carcinoma (SCC) of the cervix continues to be a major problem in many areas of the Asian-Pacific, particularly in the Indian subcontinent and Papua New Guinea, and to a lesser extent in South-East Asia, Korea and Mongolia. In contrast, levels in the developed countries of the region are low, as is also the case for the Muslim countries of Western Asia, and mainland China. Incidence generally mirrora associated mortality, although with some exceptions reflecting facilities and infrastructure for early detection. Over the last 25 years there has been a marked decrease in incidence rates across most of the Asian Pacific, although less pronounced in India than elsewhere, and there are exceptions where the incidence is on the increase. The predominant risk factor is well established to be persistent infection with a high risk 'oncogenic' type of human papilloma virus (HPV), along with multiple partners, other sexually tansmitted diseases and smoking. Consumption of vegetables, in contrast, appears to be protective. Hormonal factors may also play some role. Modifying factors may either impact on neoplasia by directly influencing the processes underlying carcinogenesis, or indirectly by affecting persistence of viral infections. For primary prevention, avoidance of repeated infections and smoking, as well as a high antioxidant intake may be beneficial. Vaccines against HPV also have promise for the future, but a better understanding of the mechanisms underlying spontaneous clearance of both infection and cervical intraepithelial neoplasia (CIN) of different grades is also essential for optimal intervention. For screening, the choice of whether the PAP smear, HPV testing or some form of visual inspection are utilized depends on the resources which are available, all approaches having their own advantages and disadvantages, but with similar sensitivity and specificity. One complication is the increase in adenocarcinoma of the cervix which has been reported in some countries, for which risk factors and most effectice screening may differ from the SCC case. A focus on high risk groups like sex workers might be warranted where financial and technical support are limited. If cervical intraepithelial neoplasias are detected then cryotherapy or the loop electrosurgical excision procedure (LEEP) are effective for their removal. Control of cancer of the cervix, however, demands that a comprehensive approach to screening and management is adopted, necessitating major training of personnel and provision of appropriate resources.

**Key Words**: Descriptive epidemiology - analytical epidemiology - risk factors - screening - vaccine

*Asian Pacific J Cancer Prev,* **5**, 349-361

## Descriptive Epidemiology

   In the country data in the International Association for Cancer Registries/APJCP supplement published after the Khon Kaen annual meeting in 2000, cervical cancer ranked number one in India, Indonesia and Thailand (Gajalakshmi et al., 2001; Sarjadi and Trihartini, 2001; Deerasamee et al., 2001), number two in the Philippines, Malaysia and Vietnam (Anh, 2001; Esteban et al., 2001, Rosemawati and Sallehudin, 2001), intermediate in Pakistan, Mongolia, Korea, Oman and Iran (Ahn, 2001; a;-Lawati et al., 2001; Bhurgri, 2001; Mosavi-Jarrahi et al., 2001; Munkhtaivan et al., 2001), and only number five in Japan (Oshima et al., 2001) and eight or more in China, Jordan and Saudi Arabia (Al Hamdan et al., 2001; Qasem, 2001; Wang, 2001). From GLOBOCAN, squamous cell carcinoma (SCC) of the cervix continues to be a major problem in many areas of the Asian-Pacific, particularly in the Indian subcontinent and Papua New Guinea, and to a lesser extent in South-East Asia, Korea and Mongolia, mortality rates generally reflecting incidence (see Figure 1 ). However, relative mortality does vary widely, with far fewer patients with cervical cancer surviving in

[1]*APOCP Coordination and Training Center apocp2000@yahoo.com,* [2]*Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute ktajima@aichi-cc.jp*

**Figure 1. Incidence (a) and Mortality (b) Rates for Cervical Cancer in the Asian Pacific**

developing countries than in the developed world. Some rates for 5 year survival are provided in Table 1. Within countries there may also be considerable differences across social groups and in different locations. For example, Aborigines in rural and remote areas of Australia are at significantly higher risk of death from cancer of the cervix than either Aboriginal women in metropolitan areas or non-Aboriginal women in any area (O'Brien et al., 2000).

The age distribution of cervical cancer cases may vary widely with the country, and in high incidence sites individuals in their late 20s and early 30s account for an appreciable amount of the burden (see Table 2). Assuming efficacy of screening for early lesions in the cervix, targeting young women for early detection of cancer development is thus clearly a high priority.

Over the last 25 year period, the incidence rates as reported in Cancer Incidence in Five Continents (Waterhouse et al., 1982; Muir et al., 1987; Parkin et al., 1992; 1997; 2002) have shown a marked tendency for decrease in many

**Table 1. Five Year Survival Rates for Cervical Cancer Patients**

| | | |
|---|---|---|
| India (Kerala) | 47% | Sankaranarayanan et al, 1995 |
| Australia | 72% | Taylor et al., 1996 |
| India (Barshi ) (90-91) | 40% | Jayant et al., 1996 |
| Earlier | 27% | |
| India (Bangalore) | 41% | Kumaraswamy et al., 1998 |
| India (Chennai) | 60% | Gajalakshmi et al., 2000 |
| Thailand (Khon Kaen) | 55% | Sriamporn et al., 2004 |

**Table 2. Burden of Cervix Cancers by Age Class\***

| Registry | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 |
|---|---|---|---|---|---|
| Tianjin | 0.1 | 0.3 | 1.0 | **3.2** | **4.1** |
| Madras | 4.4 | 12.4 | **18.6** | **14.9** | 6.1 |
| Osaka | 1.5 | 4.8 | **5.8** | **5.5** | 4.9 |
| Manila | 2.9 | **7.9** | **7.8** | 5.3 | 3.4 |
| Khon Kaen | 2.7 | **7.2** | **10.2** | **7.2** | 1.1 |
| Hanoi | 0.7 | **2.7** | **3.1** | 1.7 | 1.0 |
| Hanoi | 0.7 | **2.7** | **3.1** | 1.7 | 1.0 |

\*Incidence/100,000 x percentage of the female population
Data from Parkin et al., 1997

**Table 3. Ratios of SCC to Adenocarcinoma of the Cervix Uteri and Endometrium**

| | AC Cervix | AC Endometrium |
|---|---|---|
| China, Tianjin | 6.9:1 | 0.70:1 |
| India, Bombay | 11.9:1 | 0.13:1 |
| India, Madras | 56.9:1 | 0.06:1 |
| Israel, Non-Jews | 3.3:1 | 2.13:1 |
| Japan, Osaka | 7.7:1 | 0.37:1 |
| Singapore, Chinese | 5.7:1 | 0.41:1 |
| Thailand, Khon Kaen | 4.5:1 | 0.24:1 |
| Australia, NSW | 3.6:1 | 0.46:1 |
| Hawaii, Japanese | 2.3:1 | 0.52:1 |

Data from Parkin et al., 1997

**Figure 3. Change in Cervical Cancer Incidence with Time (Data from Cancer Incidence in Five Continents)**

Asian countries, although to a much lesser extent in India than elsewhere, and in some populations there has been an increase (see Figure 3). The decline found in countries which have no national screening program in place would point to some natural decrease in risk factor exposure. It should also be remembered, however, that high parity increases the risk of squamous-cell carcinoma of the cervix among HPV-positive women and general decline in parity might therefore partly explain the reduction in cervical cancer recently seen in many countries (Munoz et al., 2002). The situation is also to some extent complicated by the fact that adenocarcinomas of the cervix may also account for a relatively high proportion of total cervical cancer cases, and these may be on the increase (see Table 3). To a certain extent, risk factors may be shared with endometrial cancer, as suggested by their incidence ratios (Table 3). A meta-analysis comparison of squamous cell and adenocarcinomas of the cervix, revealed the latter to be less associated with smoking (Berrington de Gonzalez et al., 2004).

## Causal and Modifying Factors

*Histogenesis of Cervical Cancer*

The development of squamous cell carcinomas in the cervix is generally thought to proceed via cervical intraepithelial neoplasia (CIN) (Richart, 1968; 1990). As early lesions, atypical squamous cells of undetermined significance (ASCUS) indicate an increased risk of low-grade and high-grade squamous epithelial lesions (LSIL and

HSIL) (Cheung et al., 2004). LSIL is included in CIN 1 in the Bethesda system, the result of workshops held at the US National Cancer Institute (1989; 1993), while HSIL encompasses the more advanced CIN-2 and CIN 3 (see Figure 4).

*General*

The main 'cause' of SCC of the uterine cervix is persistent infection with one of the 'oncogenic' human papilloma viruses (HPVs) (zur Hausen, 2002), although co-factors may be necessary for initiation and to allow the virus to generate lesions which progress to cervical cancer. A great deal is known about the pathogenesis of viral involvement (Longworth and Laimins, 2004) and genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract have been reviewed recently (Wentzensen et al., 2004). The prevalence of high risk forms of the virus in Asian populations is well documented (Ghim et al., 2002; Anh et al., 2003; Shin et al., 2003).

In high risk groups like sex workers, the rates for both

**Table 4. Coincidence of Early lesions and HPV Infection in Sex Workers**

|  | LSIL | HSIL | HPV | HR-HPV |
|---|---|---|---|---|
| Sex Workers | 15.6 | 2.9 | 77.4 | 55.9 |
| Controls | 2.9 | 0.6 | 27.6 | 14.3 |

Data from Mak et al., 2004

**Figure 3. Modifying Factors Impacting on Cervical Neoplasia and Persistence of HPV Infection**

early lesions and HPV infection are high (see Table 4)( Mak et al., 2004). Although incidence rates of cervical cancer are presently low, Muslim women are as susceptible as Hindus to HPV (Duttagupta et al., 2004). Different levels of viral integration are correlated with lesion grade (Hudelist et al., 2004) and in one study of cases with CIN-2/3 confirmed by biopsy, over a 6 month period both loss and gain of virus were encountered, but final positivity correlated with outcome in terms of lesion development (Crum et al., 2004). HPV-16-immortalized genital cells are known to be responsive to the genotoxic action of known chemical carcinogens (polycyclic hydrocarbons, alkylating agents or cigarette smoke condensate) (DiPaolo et al., 1996), including examples found in cigarette smoke (Nakao et al., 1996). Furthermore, inflammation may be associated with high-grade lesions in women infected with oncogenic HPV (Castle et al., 2001). Chlamydia trachomatis infection is also a possible co-factor in the etiology of squamous cervical cancer, and its effect may be mediated by chronic inflammation (Smith et al., 2002b).

Infection with human papillomavirus precedes the development of low and high grade squamous intraepithelial lesions and the effect of genital HPV infection on CIN development is highly influenced by oncogenic viral type and high viral load (Ho et al., 1998). A sustained high viral load is consequently informative for progression to a high-grade lesion (van Duin et al., 2002). For the latter the risk is greatest in women positive for the same type of HPV on repeated testing (Kjaer et al 2002). Most infections clear spontaneously, however, and a large proportion of the women who were HPV-positive appear to have cleared the infection after one year (Sellors et al., 2003). The rate appears to be slower with high risk forms. Thus the reported median time to clearance of infection with oncogenic strains is 9.8 months, as compared to 4.3 months with non-oncogenic strains (Giuliano et al., 2002a). Surgical treatment of CIN usually results in clearance of HPV infection within 3 months and human papillomavirus DNA testing may be useful as a

rapid intermediate end point for monitoring the efficacy of treatments (Elfgen et al., 2002). On average, HPV DNA detection persists longer than related cytologic abnormalities (Schiffman et al., 2002).

Similarly to the virus itself, human papillomavirus (HPV)-associated cervical intraepithelial neoplasia(CIN) lesions in normal women may spontaneously regress, but a small number obviously do persist and progress to invasive cancer. Neutralizing antibodies against oncogenic human papillomavirus are a possible determinant of the fate of low-grade cervical intraepithelial neoplasia (Kawana et al., 2002) and cellular immunity to HPV-16 E7 is significantly associated with clinical and cytological resolution of HPV-induced CIN (Hopfl et al., 2000). Cell mediated immune responses to E7 peptide correlate significantly with regression of disease and with resolution of viral infection within 12 months (Kadish et al., 2002).

*Specific Risk and Beneficial Factors*
*Sexual Behaviour*
a) Direct Influence on Cervical Cancer Development.
Abnormal smears and high risk HPV have been found to be significantly more prevalent in sex workers than in controls in Belgium, Japan, Mexico and Thailand (Ishi et al., 2000; Juarez-Figueroa et al., 2001; Thomas et al., 2001b; Mak et al., 2004), It has been suggested that HSV-2 infection may act in conjunction with HPV infection to increase the risk of invasive cervical carcinoma on the basis of an analysis of seven case-control studies (Smith et al, 2002a), although in other studies, it was concluded that the virus did not play a role in cervical carcinogenesis (Lehtinen et al., 2002; Tran-Than et al., 2003). As noted above, other sexually transmitted diseases could also play roles as co-factors. For example squamous cell SCC, but not AC risk increases with increasing C. trachomatis antibody titers (Smith et al., 2004).
b) Influence on HPV Infection. Incident infection with carcinogenic HPV has been shown to be highest in sexually active women aged 15-19 years, and risk factors are

consistent with a sexually transmitted infection. Lifetime number of sexual partners is associated with oncogenic HPV infection. In contrast, non-oncogenic HPV infection appeared to be associated with recent sexual activity, suggesting a more transient nature (Giuliano et al., 2002b).

*Hormones*

a) <u>Direct Influence on Cervical Cancer Development</u>. Long-term use of oral contraceptives could be a cofactor that increases risk of cervical carcinoma by up to four-fold in women who are positive for cervical HPV DNA (Moreno et al., 2002). However, it has been concluded that there is no evidence for a strong positive or negative association between HPV positivity and ever use or long duration use of oral contraceptives (Green et al., 2003)

b) <u>Influence on HPV Infection</u>. Included in factors that may predispose to persistent, oncogenic HPV-16 or -18 infection are estrogens, or progestins in the presence of estrogens (Thomas et al., 2001a).

*Smoking*

a) <u>Direct Influence on Cervical Cancer Development</u>. Cigarette smoking is a factor, which, independently of HPV infection, influences the treatment outcome of CIN (Acladius et al., 2002). The finding that burning wood in the kitchen as also a risk factor is interesting in this context (Velema et al., 2002). Smoking is associated with both CIN1 and CIN2-3, and cigarette by-products may affect the early evolution of HPV-related lesions, possibly by increasing the rate of cell turnover (Harris et al., 2004). Among women attending a colposcopy clinic, the risk of detection of high grade lesions increases with the spouse's cigarette-smoking habit (Tay and Tay, 2004). Also lifetime exposure to environmental tobacco smoke was established as a major factor in cervical neoplasia in non-smoking women in Taiwan (Wu et al., 2003). The overall conclusion of an IARC multi-center study was that smoking increases the risk of cervical cancer among HPV positive women (Plummer et al., 2003).

b) <u>Influence on HPV Infection</u>. Smoking may also promote early cervical carcinogenic events by increasing duration of oncogenic HPV infections and decreasing the probability of their clearance (Giuliano et al., 2002c).

*Diet*

a) <u>Direct Influence on Cervical Cancer Development</u>. It has been suggested that high plasma levels of antioxidants may reduce the risk of cervical lesions independent of HPV infection (Goodman et al., 1998). Lycopene and perhaps vitamin A may play a protective role in the early stages of cervical carcinogenesis. (Kanetsky et al., 1998) and vitamins C and E (alpha-tocopherol) appear to independently exert protective effects against development of CIN (Ho et al., 1998). The latter vitamin was found to be significantly inversely associated with grade of cervical dysplasia (Giuliano et al., 1997). In another study, dietary intake of foods rich in total vitamin A, and particularly those with high-retinol content, reduced the risk of in-situ cervical

cancer, and at the highest level of intake appeared to inhibit progression to invasion (Shannon et al., 2002).

b) <u>Influence on HPV Infection</u>. In one study, concentrations of serum beta-carotene, beta-cryptoxanthin, lutein, and alpha- and gamma-tocopherol were significantly lower among women two times HPV positive compared with either two times HPV negative or one time HPV positive (Giuliano et al., 1997). Circulating vitamin B12 levels also demonstrated an inversely associated with HPV persistence after adjusting for age, age at first intercourse, marital status, cigarette smoking status, race, and body mass index. No significant associations were observed between HPV persistence and dietary intake of folate, vitamin B12, vitamin B6, or methionine from food alone or from food and supplements combined or from circulating folate in another case, however(Sedjo et al., 2002).

*Pharmaceutical Intervention*

a) <u>Direct Influence on Cervical Cancer Development</u>. Lower alpha-tocopherol levels in in women with cervical intraepithelial neoplasia have been reported (Palan et al., 2004), consistent with findings of decreased antioxidant concentrations and increased oxidative stress (Sgambato et al., 2004). Women with high circulating concentrations of cryptoxanthin and tocopherol may be at a reduced risk of atypical squamous cells of undetermined significance (ASCUS) and cervical dysplasia (Goodman et al., 1998; 2000). The cervix in fact has many advantages as a target for chemoprevention of squamous cell carcinogenesis, since premalignant lesions are readily identifiable and can be followed (Mitchell et al., 1995). Direct application of preventive agents is feasible, with the possibility of repeated biopsy. As a marker, Ki-67 immuno-quantitation in CIN 1 or CIN 2 has strong independent prognostic value for progression (Kruse et al., 2003).

Regarding trials which have already been performed, intravaginal dehydroepiandrosterone was found to be safe and well tolerated and to possibly promote regression of low-grade cervical lesions (Suh-Bergmann et al., 2003). In a preliminary study in India, vitamin E supplementation inhibited progression of CIN I and I (Ganguly et al., 2001). A statistically significant regression of CIN in patients treated with indole-3-carbinol orally compared with placebo has also been reported (Bell et al., 2000), although in another study, the antioxidant beta-carotene did not enhance the regression of high-grade CIN, especially in HPV-positive subjects (Keefe et al., 2001).

b) <u>Influence on HPV Infection</u>. Antiviral agents like Cidofovir have potential for treatment of severe HPV-induced proliferative lesions in the cervix, as well as in other sites of the body (Snoek et al., 2001). Intramuscular injections of interferon beta are effective for treating recurrent HPV, particularly when associated with CIN (Gonzales-Sanchez et al., 2001). Topical immunotherapy is also conceivable (Hengge et al., 2001). It has been argued that chemopreventive agents to decrease HPV viral protein

**Table 5. Data for Comparisons of Screening Modalities**

| Country | | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|
| Africa[1] | VIA | 76.8 | 85.5 | 9.4 | 99.5 |
| | VILI | 91.7 | 85.4 | 10.9 | 99.8 |
| India[1] | VIA | 55.7 | 82.1 | - | >98 |
| | VIAM | 60.7 | 83.2 | - | >98 |
| | Pap | 29.5 | 92.3 | - | >98 |
| Iran[2] | Pap | 72.0 | 90.2 | | |
| | VIA | 74.3 | 94.0 | | |
| Finland[3] | HC | 85.2 | 67.2 | 4.5 | 99.6 |
| | PCR | 74.0 | 64.1 | 3.6 | 99.3 |
| France[4] | HC | | | | 99.8 |
| | Pap | | | | 99.2 |
| Korea[5] | HPV | 92.4 | 52.4 | 49.3 | 93.2 |
| | Pap | 76.3 | 65.8 | 52.8 | 84.7 |
| | Both | 97.8 | 36.7 | 49.2 | 97.3 |

1 Sankaranayanan et al 2004, 2 Ghaemmaghami et al., 2004, 3 Kulmala et al 2004, 4 Clavel et al 2001 5 Lee et al 2004

expression warrant particular attention (Follen et al., 2002). Finally, in the future, the possibility of applying specific vaccines will become increasingly feasible and indeed, the first steps have already been taken (Koutsky et al., 2002). If HPV vaccines are successful, the balance of cervical cancer prevention may shifts from traditional screening to primary prevention coupled with HPV testing (Crum et al., 2003).

## Screening and Resection

There are three main modalities for screening for early lesions for cervical cancer, in increasing order of requirement for equipment and infrastructure support: visual inspection with acetic acid or Lugol's iodine; the Papanicalou smear; and the HPV test, either by hybrid capture or PCR. Numbers of comparisons have already been made among tests (Danneker et al., ??; Clavel , Lee Ghaemmaghami et al ???, Basu et al., 2003; Sankaranarayanan et al., 2004, Kulmala et al ) with generally similar results obtained for sensitivity and specificity (see Table 5). The need for controlled trials for evidence based cervical cancer prevention has been stressed (Franco, 2004). Costa et al., 2000) prompted the authors to conclude that no single test can be adopted to replace the PAP smear in routine clinical studies. Choice of test is complicated by cultural variables and in some cases self-sampling may be of assistance in improving compliance (Dzuba et al., 2002). One device for this purpose has already been tested and shown to give reliable results (Pengsaa et al., 1997), especially in educated women (Sanchaisuriya et al., 2004). Gravitt et al (2001) also demonstrated that a self-collected Dacron swab sample of cervicovaginal cells is a technically feasible alternative to clinician-administered cervical cell collection for studies of the natural history studies of HPV and cervical cancer.

It has been argued that the most effective means for early detection in rural areas of developing countries is direct visual inspection with acetic acid or Lugol's iodine (Wesley et al,. 1997; Sankaranarayanan et al 1998; Chirenje et al., 1999; Singh et al., 2001). Visual inspection can be performed reliably by trained paramedical workers and doctors and is an effective screening option in low resource settings (Bhatla et al., 2004).

Choice of test is complicated by cultural variables and in some cases self-sampling may be of assistance in improving compliance (Dzuba et al., 2002). One device for this purpose has already been tested and shown to give reliable results (Pengsaa et al., 1997), especially in educated women (Sanchaisuriya et al., 2004). Gravitt et al (2001) also demonstrated that a self-collected Dacron swab sample of cervicovaginal cells is a technically feasible alternative to clinician-administered cervical cell collection for studies of the natural history studies of HPV and cervical cancer.

With regard to the type of Pap smear, no significant difference in rates of false positive diagnoses between conventional and liquid-based samples was detected in one study (Mount et al., 2004). However, Sass (2004) found Thin-layer Pap Sure-Path to detect significantly more cases of LSIL and HSIL than conventional smears without compromising specificity. The ASCUS/SIL ratio and unsatisfactory rate declined dramatically. Further evidence in support of the use of the ThinPrep Pap test to enhance the efficiency of cervical cytology screening, has been provided by a focus terms of time taken (Cheung et al., 2003). Reprocessing unsatisfactory ThinPrep Papanicolaou test specimens increases sample adequacy and detection of significant cervicovaginal lesions (Islam et al., 2004). As an adjunct, cervical acid phosphatase adds to the visibility of the Pap test and enables cytoscreeners to significantly improve the detection of positive/abnormal specimens and reduce false negative rates (Markovic and Markovic, 2003-4). Recent results suggest that expression of matrix metalloproteinase 2 can distinguish CIN 1, 2, and 3 grades (Gaiotto et al., 2004) and HPV 16 testing has also been proposed as an adjunct to predict progression to CIN 3 (Tanaka et al., 2004).

In another study, immunohistochemical detection of p16 was more sensitive and specific than the HPV status in cervical lesions using a liquid-based method as well as tissue samples (Yoshida et al., 2004). P16(INK4a) as an adjunct marker in liquid-based cervical cytology (Sahebali et al., 2004) and a putative molecular biomarker of cervical adenocarcinoma whose overexpression appears to primarily reflect HPV-induced cell cycle dysregulation (Schorge et al., 2004). A correlation exists between the expression of p16(INK4a) and pRb in cervical neoplasias (Tringler et al., 2004). Furthermore, aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis (Lea et al., 2004).

While adenocarcinoma in situ is not as easily recognized as CIN (Renshaw et al., 2004), they share many characteristic features on conventional smears (Ozkan et al., 2004). However, lower protection of cytological screening was found in a case-control study in Italy (Zappa et al., 2004).

With biennial screening, Mitchell et al (2003) estimated that a 46% reduction in the cumulative incidence of invasive adenocarcinoma could be achieved, and with annual screening, a 65% reduction.

Due to high relative sensitivity of the HPV, only very few histologically confirmed high grade lesions are detected among HPV negatives using simultaneous cytology and thus the negative predictive value is particularly good (Nieminen et al 2004). On the other hand, using HPV DNA test alone would lead to multifold amounts of referrals for colposcopy. The screening sensitivity can be further improved by combining cytology with HPV DNA testing, especially for detecting cancer precursors in women older than 60 years. (Lee et al., 2004). Comparison of HPV testing by chromogenic in situ hybridization (CISH) and by hybrid capture (HC) revealed advantages and disadvantages for both (Schiller et al., 2004).

Whatever the methodological approach adopted, opportunistic screening is known to have limited efficacy, with overscreening of a minority as an added disadvantage (Adab et al., 2004). Regarding compliance with testing, more research into cultural determinants would appear to be warranted. In a recent review of the literature on cancer screening, Moore et al (2003) found that very few papers focused on intervention. In one study in South Africa, liteners of a radio-drama were more likely to report attending screening, whereas a photo-comic was ineffective (Risi et al., 2004). The authors concluded that research should concentrate not only on achieving high levels of exposure to health messages, but also on investigating the links between exposure and action.

*Resection*

It is essential that a comprehensive management system be in place for treatment after screening if the latter is to have any meaning (see Figure 4). For resection of CIN lesions, both cryotherapy and the loop electric excision procedure (LEEP) are widely performed. LEEP avoids the possibility of under-treatment and is associated with an acceptable over-treatment rate, especially for postmenopausal women (Ng et al., 2004). Another advantage is that tissue is available for histopathological assessment, although negative LEEP is associated with a recurrence rate similar to that of a positive LEEP (Livasy et al., 2004). Both HPV and Pap tests perform well in detecting residual or recurrent disease after LEEP and their combination did not increase sensitivity (Sarian et al., 2004). Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following LEEP (Farley et al., 2004). Concluding a systematic review of the literature Paraskevaidis et al (2004) found a positive HPV test, even in the presence of normal cytology, to accurately predict treatment failure. Similarly in Japan persistent infection with a high-risk type of HPV is a predictor of recurrence (Nagai et al., 2004).Cytology and colposcopy may still be needed in order to rule out false positive and false negative results. Subjects with negative findings at cytology, colposcopy and HPV testing are at negligible risk of recurrence and might return safely to the standard screening protocol (Cecchini et al., 2004).

In the resource rich setting a number of other modalities are applicable. For example, the whole-body FDG PET scan has been shown to be a sensitive imaging approach for the detection of recurrent cervical carcinoma in both symptomatic as well as asymptomatic women (Unger et al., 2004).

## Vaccine Development

The HPV types that cause cervical cancer are sexually transmitted, but it should be borne in mind that there is little evidence that infection can be avoided by behavioural



**Figure 4. Comprehensive Management of Premalignant Lesions (after Sellors and Sankaranayanan, 2003)**

**Primary Prevention**  **Secondary Prevention**



**Figure 5. Measures for Primary and Secondary Prevention of Cervical Cancer**

changes, such as condom use (Franceschi et al., 2003). The 15 most common types of high risk HPV acoss the world are , in descending order of frequency, 16, 18, 45, 31, 33, 52, 58, 35, 59, 56, 39, 51, 73, 68 and 66 (Munoz et al 2004). Higher than average proportions of type 16 are found in northern Africa, of type 18 in south Asia, of type 45 in sub-Saharan Africa and of type 31 in Central/South America. It has been concluded by Munoz and the IARC collaborative group (2004) that a vaccine including types 16 and 18 could potentially prevent 71% of cervical cancers worldwide, but its impact would be higher in Asia and Europe/North America. In contrast, a vaccine containing the 7 most common HPV types would prevent about 87% of cervical cancers worldwide, with little regional variation. Human papillomavirus vaccines for both prevention and therapy of cervical cancers are no longer a dream  (Mandic, Vujkov, 2004) and  the first steps have already been taken (Koutsky et al., 2002). If HPV vaccines are successful,  the balance of cervical cancer prevention may shift from traditional screening to primary prevention coupled with HPV testing (Crum et al., 2003).Trials have shown vaccines to be acceptable in certain cultural milieus (Lazcano-Ponce et al., 2001; Gudmundsdottir et al., 2003).

Specific strategies have been proposed for both screening and therapeutic purposes (Schreckenberger and Kaufmann, 2004). Transmission of papillomavirus may be prevented by generation of antibodies aganst capsid proteins L1 and L2 that neutralize viral infection (Roden et al., 2004). However, because the capsid proteins are not expressed at detectable levels by infected basal keratinocytes or in HPV-transformed cells, therapeutic vaccines generally target nonstructural early viral antigens.A DNA vaccine linking calreticulin to E7 (CRT/E7) may be a suitable candidate for human trials for the control of HPV infections and HPV-associated lesions (Kim et al., 2004). In a phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine, it was generally well-tolerated and highly immunogenic (Ault et al., 2004).  It is important, however, to start as soon as possible simpler trials designed to demonstrate the effectiveness of HPV vaccine in field conditions in developing countries which suffer the major burden of mortality from cervical cancer  (Franceschi et al., 2003).

## Cervical Cancer Control

From the information which is already available in the research literature, concrete measures for both primary and secondary prevention of  cervical cancer can be proposed (see Figure 5). These include safe sexual behaviour, refraining from smoking and increasing intake of vegetables in the general population. For screening, the most appropriate modality for the prevailing economic and social conditions needs to be selected and  a conprehensive program put in place to ensure the greatest benefit. However, a recent survey indicated that the recommendations as currently given are met in only very few European countries (Anttila et al 2004) and the situation in most of the developing or partially developed world is even less rosy. Health authorities need to consider stronger measures and incentives than those laid out in the current set of recommendations.

The implications are that public understanding of cervical cancer, psychosocial factors associated with screening, and the potential impact on screening uptake, are all issues which require greater stress (Waller et al., 2004). The importance of education has been stressed, for example to persuade young women to take part in HPV clinical trials (Hoover et al., 2000). The role of biobehavioral factors in the persistence and progression of HPV infection as well as possible interventions to minimize the risk of persistence, as well as primary prevention of HPV continue to be major challenges (Moore et al., 2003).

In the Asian Pacific specific programs like that to increase Pap screening behavior among women in Taiwan need to be emphasized. Intervention mapping, an innovative process of design, guided the development of this program, including a needs assessment identifying factors influencing Pap screening behavior relevant to Chinese women (Hou et al.,

2004). It features methods such as information transmission, modeling, persuasion, and facilitation, and encompasses strategies includlike direct mail communication, role-model stories and testimonials, and a telephone-counseling component. In this type of endeavour particular emphasis should be placed on use of nurses and midwives for both primary prevention and screening (Turkistanlı et al., 2003).

To conclude, the idea of the Practical Prevention Project (Tajima and Moore, 2001), reaching into the community to provide information as well as facilitate access to primary and secondary preventive measures for cervical cancer remains of prime importance.

## References

Acladious NN, Sutton C, Mandal D, et al (2002). Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). *Int J Cancer,* **98**, 435-9.

Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ (2004). Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. *Med Care*, **42**, 600-9.

Ahn Y-O (2001). Population-nased cancer registries in Korea. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 39-42.

Anh PH (2001). Cancer registration in Vietnam. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 85-9.

Anh PTH, Hieu NT, Herrero R, et al (2003). Human papillomavirus infection among women in South and North Vietnam. *Int J Cancer*, **104**, 213-20.

Al Hamdan N, Bazarbashi S, Ajarim D, et al (2001). Cancer registration in Saudi Arabia. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 61-4.

al-Lawati JA, al-Shaqsi, B N al-Siyabi (2001).Cancer registration in the Sultanate of Oman. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 71-4.

Anttila A, Ronco G, Clifford G, et al (2004). Cervical cancer screening programmes and policies in 18 European countries. *Br J Cancer*, **91**, 935-41.

Ault KA, Giuliano AR, Edwards RP, et al (2004). A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. *Vaccine*, **22**, 3004-7.

Basu PS, Sankaranarayanan R, Mandal R, et al (2003) Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. *Int J Gynecol Cancer*, **13**, 626-32.

Bell MC, Crowley-Nowick P, Bradlow HL, et al (2000). Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. *Gynecol Oncol*, **78**, 123-9.

Berrington de Gonzalez A, Sweetland S, Green J (2004). Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. *Br J Cancer*, **90**,1787-91.

Bhatla N, Mukhopadhyay A, Joshi S, et al (2004). Visual inspection for cervical cancer screening: evaluation by doctor versus paramedical worker. *Indian J Cancer*, **41**, 32-6.

Bhurgri Y (2001). Cancer registration in Pakistan. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 51-4.

Castle PE, Hillier SL, Rabe LK, et al (2001). An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). *Cancer Epidemiol Biomarkers Prev,* **10**, 1021-7.

Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S (2004). Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. *Tumori*, **90**, 225-8.

Cheung AN, Szeto EF, Leung BS, Khoo US, Ng AW (2003). Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population. *Cancer*, **99**, 331-5.

Cheung AN, Szeto EF, Ng KM, et al (2004). Atypical squamous cells of undetermined significance on cervical smears: follow-up study of an Asian screening population. *Cancer*, **102**, 74-80.

Chirenje ZM, Chipato T, Kasule J, Rusakaniko S (1999). Visual inspection of the cervix as a primary means of cervical cancer screening: results of a pilot study. *Cent Afr J Med*, **45**, 30-3.

Clavel C, Masure M, Bory JP, et al (2001). Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. *Br J Cancer*, **84**, 1616-23.

Costa S, Sideri M, Syrjanen K, et al (2000). Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. *Acta Cytol*, **44**, 310-8.

Crum CP, Abbott DW, Quade BJ (2003). Cervical cancer screening: from the Papanicolaou smear to the vaccine era. *J Clin Oncol*, **21** (10 Suppl), 224-30.

Crum CP, Beach KJ, Hedley ML, et al (2004). Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. *J Infect Dis*, **189**, 1348-54.

Deerasamee S, Martin N, Sontipong S, et al (2001). Cancer registration in Thailand. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 79-84.

DiPaolo JA, Popescu NC, Woodworth CD, Zimonjic DB (1996). Papillomaviruses and potential copathogens. *Toxicol Lett,* **88**, 1-7.

Duttagupta C, Sengupta S, Roy M, et al (2004). Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India. *Int J Gynecol Cancer*, **14**, 293-303.

Dzuba IG, Diaz EY, Allen B, et al (2002). The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. *J Womens Health Gend Based Med*, **11**, 265-75.

Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J (2002). Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. *Obstet Gynecol*, **100**, 965-71.

Esteban DB, Laudico AV, Uy NA, Benabay L (2001). Cancer registration in the Philippines. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 55-60.

Farley J, Uyehara C, Hashiro G, et al (2004). Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. *Gynecol Oncol*, **92**, 596-602.

Fidaner C, Eser SY, Parkin DM (2001). Incidence in Izmir in 1993-1994: first results from Izmir Cancer Registry. *Eur J Cancer,* **37**, 83-92.

Follen M, Vlastos AT, Meyskens FL Jr, Atkinson EN, Schottenfeld D (2002).Why phase II trials in cervical chemoprevention are negative: what have we learned? *Cancer Causes Control,* **13**, 855-73.

Franceschi S, Clifford G, Plummer M (2003). Prospects for primary

prevention of cervical cancer in developing countries. S*alud Publica Mex*, *45 Suppl 3*, S430-6.

Franco EL (2004). Randomized controlled trials of HPV testing and Pap cytology: toward evidence-based cervical cancer prevention. *Int J Cancer*, **110**, 1-2.

Gaiotto MA, Focchi J, Ribalta JL, et al (2004). Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. *Am J Obstet Gynecol*, **190**, 1278-82.

Gajalakshmi V, Rajaraman S, Shanta V (2000). A survival study of cervical cancer in Chennai, India. *Indian J Cancer*, **37**, 158-64.

Gajalakshmi V, Shantha V, Swaminathan R (2001). Cancer registration in India. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 13-20.

Ganguly C, Dutta K, Sanyal U, et al (2001). Response of cervical intra-epithelial lesions to vitamin E supplementation -  a preliminary report. *Asian Pacific J Cancer Prev*, **2**, 305-8.

Ghaemmaghami F, Behtash N, Modares Gilani M, et al (2004). Visual inspection with acetic acid as a feasible screening test for cervical neoplasia in Iran. *Int J Gynecol Cancer*, **14**, 465-9.

Ghim S-J, Basu PS, Jenson AB (2002) Cervical cancer: etiology, pathogenesis, treatment, and future vaccines. *Asian Pacific J Cancer Prev*, **3**, 207-14.

Giuliano AR, Harris R, Sedjo RL, et al (2002a). Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. *J Infect Dis*, **186**, 462-9.

Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P (2002b). Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. *Cancer Epidemiol Biomarkers Prev*, **11**, 930-4.

Giuliano AR, Papenfuss M, Nour M, et al (1997). Antioxidant nutrients: associations with persistent human papillomavirus infection. *Cancer Epidemiol Biomarkers Prev*, **6**, 917-23.

Giuliano AR, Sedjo RL, Roe DJ, et al (2002c). Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). *Cancer Causes Control*, **13**, 839-46.

Gonzalez-Sanchez JL, Martinez-Chequer JC, Hernandez-Celaya ME, Barahona-Bustillos E, Andrade-Manzano AF (2001). Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus. *Obstet Gynecol*, **97**, 621-4.

Goodman MT, Kiviat N, McDuffie K, et al (1998). The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii. *Cancer Epidemiol Biomarkers Prev,* **7,** 537-44.

Goodman MT, McDuffie K, Hernandez B, et al (2000).The association of plasma micronutrients with the risk of cervical Atypical Squamous Cells of Undetermined Significance (ASCUS). *Asian Pacific J Cancer Prev*, **1**, 339-47.

Gravitt PE, Lacey JV Jr, Brinton LA, et al ( 2001). Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. *Cancer Epidemiol Biomarkers Prev*, **10**, 95-100.

Green J, Berrington De, Gonzalez A, et al (2003). Human papillomavirus infection and use of oral contraceptives. *Br J Cancer*, **88**, 1713-20.

Gudmundsdottir T, Tryggvadottir L, Allende M, et al (2003). Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. *Acta Obstet Gynecol Scand*,  **82**, 345-50.

Harris TG, Kulasingam SL, Kiviat NB, et al (2004). Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. *Am J Epidemiol*, **159**, 834-42.

Hengge UR, Benninghoff B, Ruzicka T, Goos M (2001). Topical immunomodulators--progress towards treating inflammation, infection, and cancer. *Lancet Infect Dis*, **1**, 189-98.

Ho GY, Palan PR, Basu J, et al (1998). Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. *Int J Cancer*, **78**, 594-9.

Hoover DR, Carfioli B, Moench EA (2000). Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. *Health Care Women Int*, **21**, 375-91.

Hopfl R, Heim K, Christensen N, et al (2000). Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.  *Lancet*, **356**, 1985-6.

Hou SI, Fernandez ME, Parcel GS (2004). Development of a cervical cancer educational program for Chinese women using intervention mapping. *Health Promot Pract*, **5**, 80-7.

Hudelist G, Manavi M, Pischinger KI, et al (2004). Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. *Gynecol Oncol*, **92**, 873-80.

Ishi K, Suzuki F, Saito A, Kubota T (2000). Prevalence of human papillomavirus infection and its correlation with cervical lesions in commercial-sex workers in Japan. *J Obstet Gynaecol Res*, **26**, 253-7.

Islam S, West AM, Saboorian MH, Ashfaq R (2004). Reprocessing unsatisfactory ThinPrep Papanicolaou test specimens increases sample adequacy and detection of significant cervicovaginal lesions. *Cancer*, **102**, 67-73.

Jayant K, Rao RS, Nene BM, Dale PS, Nandakumar A (1996). Improved survival in cervical cancer cases in a rural Indian population. *Br J Cancer*, **74**, 285-7.

Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, et al (2001). Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. *Sex Transm Dis*, **28**, 125-30.

Kadish AS, Timmins P, Wang Y, et al (2002). Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. *Cancer Epidemiol Biomarkers Prev*, **11**, 483-8.

Kanetsky PA, Gammon MD, Mandelblatt J, et al (1998). Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. *Nutr Cancer,* **31**, 31-40.

Kawana K, Yasugi T, Kanda T, et al (2002). Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. *Biochem Biophys Res Commun,* **296**, 102-5.

Keefe KA, Schell MJ, Brewer C,  et al  (2001). A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev,* **10**, 1029-35.

Kim JW, Hung CF, Juang J, et al (2004). Comparison of HPV DNA vaccines employing intracellular targeting strategies. *Gene Ther*, **11**, 1011-8.

Kjaer SK, van den Brule AJ, et al (2002). Type specific persistence of high risk human papillomavirus (HPV) as indicator of high

grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. *BMJ,* **325**, 572.

Koutsky LA, Ault KA, Wheeler CM, et al ( 2002). A controlled trial of a human papillomavirus type 16 vaccine. *N Engl J Med*, **347**, 1645-51.

Kruse AJ, Baak JP, Janssen EA, et al (2003). Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. *J Pathol,* **199**, 462-70.

Kulmala SM, Syrjanen S, Shabalova I, et al (2004). Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. *J Clin Microbiol*, **42**, 2470-5.

Kumaraswamy, Nandakumar A, Venugopal T, Viswanathan N (1998). Survival in cancer of the cervix: treatment in a population-based cancer registry in a developing country (Bangalore, India). *Cancer Causes Control*, **9**, 117-23.

Lazcano-Ponce E, Rivera L, et al (2001). Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. *Arch Med Res*, **32**, 243-7.

Lea JS, Coleman R, Kurien A, et al (2004).Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. *Am J Obstet Gynecol*, **190**, 674-9.

Lee KJ, Lee JK, Saw HS (2004). Can human papillomavirus DNA testing substitute for cytology in the detection of high-grade cervical lesions? *Arch Pathol Lab Med*, **128**, 298-302.

Lehtinen M, Koskela P, Jellum E, et al (2002). Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. *Am J Epidemiol*, **156**, 687-92.

Livasy CA, Moore DT, Van Le L (2004).The clinical significance of a negative loop electrosurgical cone biopsy for high-grade dysplasia. *Obstet Gynecol*, **104**, 250-4.

Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. *Microbiol Mol Biol Rev*, **68**, 362-72.

Mak R, Van Renterghem L, Cuvelier C (2004). Cervical smears and human papillomavirus typing in sex workers. *Sex Transm Infect*, **80**, 118-20.

Mandic A, Vujkov T (2004). Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? *Ann Oncol*, **15**, 197-200

Markovic O, Markovic N ( 2003-2004). Cervical acid phosphatase: a biomarker of cervical dysplasia and a potential surrogate endpoint for colposcopy. *Dis Markers*, **19**, 279-86.

Mitchell H, Hocking J, Saville M (2003). Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. *Cancer*, **99**, 336-41.

Mitchell MF, Hittelman WN, Lotan R, et al (1995). Chemoprevention trials in the cervix: design, feasibility, and recruitment. *J Cell Biochem Suppl,* **23**, 104-12.

Moore MA, Kunimoto T, Tsuda H (2003). Cancer screening literature in the period 2000-2002; pointers to future research avenues. *Asian Pacific J Cancer Prev*, **4**, 57-60.

Moore MA, Tajima K, Anh PH, et al (2003). Grand challenges in global health and the Practical Prevention Program? Asian focus on cancer prevention in females of the developing world. *Asian Pacific J Cancer Prev*, **4**, 153-65.

Moreno V, Bosch FX, Munoz N, et al (2002). Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. *Lancet*, **359**, 1085-92.

Mosavi-Jarrahi A, Mohagheghi MA, Zeraatti H, Mortazavi H (2001). Cancer registration in Iran. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 25-9.

Mount S, Harmon M, Eltabbakh G, Uyar D, Leiman G (2004). False positive diagnosis in conventional and liquid-based cervical specimens. *Acta Cytol*, **48**, 363-71.

Muir CS, Waterhouse J, Mack T, Powell J, Whelan SL (Eds) (1987). Cancer Incidence in Five Continents Vol. V. IARC Scientific Publications No 88. IARC, Lyon.

Munkhtaivan A, Erdentuya S, Ozzi-Delger T (2001). Cancer registration in Mongolia. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 47-50.

Munoz N, Bosch FX, Castellsague X, et al (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. *Int J Cancer*, **111**, 278-85.

Munoz N, Franceschi S, Bosetti C, et al (2002). Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. *Lancet,* **359**, 1093-101.

Nagai N, Mukai K, Oshita T, Shiroyama Y, Ohama K (2004). Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III - A prospective study. *Int J Mol Med*, **13**, 589-93.

Nakao Y, Yang X, Yokoyama M, Pater MM, Pater A (1996). Malignant transformation of human ectocervical cells immortalized by HPV 18: in vitro model of carcinogenesis by cigarette smoke. *Carcinogenesis,* **17**, 577-83.

National Cancer Institute Workshop (1989). The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. *JAMA*, **262**, 931-4.

National Cancer Institute Workshop (1993). The Bethesda system for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, 1991. *Acta Cytol*, **37**, 115-124.

Ng KY, Chang CK, Chen J, Wang PH, Teng SW (2004). Is direct large loop electric excision for the transformation zone reasonable in the investigation of high-grade squamous intraepithelial lesions in cervical smears? *Eur J Gynaecol Oncol*, **25**, 61-5.

Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A (2004). Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. *BJOG*, **111**, 842-8.

O'Brien ED, Bailie RS, Jelfs PL (2000). Cervical cancer mortality in Australia: contrasting risk by Aboriginality, age and rurality. *Int J Epidemiol*, **29**, 813-6.

Ohshima A, Tsukuma H, Ajiki W, for the Research group for Cancer Registration in Japan (2001). Cancer registration in Japan. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 31-6.

Ozkan F, Ramzy I, Mody DR (2004). Glandular lesions of the cervix on thin-layer Pap tests. Validity of cytologic criteria used in identifying significant lesions. *Acta Cytol*, **48**, 372-9.

Palan PR, Woodall AL, Anderson PS, Mikhail MS (2004). Alpha-tocopherol and alpha-tocopheryl quinone levels in cervical intraepithelial neoplasia and cervical cancer. *Am J Obstet Gynecol*, **190**, 1407-10.

Paraskevaidis E, Arbyn M, Sotiriadis A, et al (2004) The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. *Cancer Treat Rev*, **30**, 205-11.

Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (Eds) (1992). Cancer Incidence in Five Continents Vol. VI. IARC Scientific Publications No 120. IARC, Lyon.

Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (Eds) (1997).

Cancer Incidence in Five Continents Vol. VII. IARC Scientific Publications No 143. IARC, Lyon.

Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (Eds) (2002). Cancer Incidence in Five Continents Vol. VIII. IARC Scientific Publications No 155. IARC, Lyon.

Pengsaa P, Vatanasapt V, Sriamporn S, et al (1997). A self-administered device for cervical cancer screening in northeast Thailand. *Acta Cytol*, **41**, 749-54.

Plummer M, Herrero R, Franceschi S, et al (2003) Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. *Cancer Causes Control*, **14**, 805-14.

Qasem MB (2001). Cancer registration in Jordan. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 37-8.

Renshaw AA, Mody DR, Lozano RL, et al (2004). Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. *Arch Pathol Lab Med*, **128**, 153-7.

Richart RM (1968). Natural history of cervical intraepithelial neoplasia. *Clin Obstet Gynecol*, **5**, 748-84.

Richart RM (1968). A modified terminology for cervical intraepithelial neoplasia. *Obstet Gynecol*, **75**, 113-3.

Risi L, Bindman JP, Campbell OM, et al (2004). Media interventions to increase cervical screening uptake in South Africa: an evaluation study of effectiveness. *Health Educ Res*, **19**, 457-68.

Roden RB, Ling M, Wu TC (2004). Vaccination to prevent and treat cervical cancer. *Hum Pathol*, **35**, 971-82.

Rosemawati A, Sallehudin AB (2001). Cancer registration in Malaysia. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 43-5.

Sahebali S, Depuydt CE, Segers K, et al (2004). P16INK4a as an adjunct marker in liquid-based cervical cytology. *Int J Cancer*, **108**, 871-6.

Sanchaisuriya P, Pengsaa P, Sriamporn S, et al (2004) Experience with a self-administered device for cervical cancer screening by Thai women with different educational backgrounds. *Asian Pac J Cancer Prev*, **5**, 144-50.

Sankaranarayanan R, Basu P, Wesley RS, et al (2004). Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. *Int J Cancer*, **110**, 907-13.

Sankaranarayanan R, Nair MK, Jayaprakash PG, et al (1995). Cervical cancer in Kerala: a hospital registry-based study on survival and prognostic factors. *Br J Cancer*, **72**, 1039-42.

Sankaranarayanan R, Rajkumar R, Theresa R, et al (2004). Initial results from a randomized trial of cervical visual screening in rural south India. *Int J Cancer*, **109**, 461-7.

Sankaranaraynan R, Wesley R, Somanthanan T, et al (1998). Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. *Cancer*, **83**, 2150-6.

Sarian LO, Derchain SF, Andrade LA, et al (2004). HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. *Gynecol Oncol*, **94**,181-6.

Sarjadi, Trihartani P (2001). Cancer registration in Indonesia. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 21-4.

Sass MA (2004). Use of a liquid-based, thin-layer Pap test in a community hospital. Impact on cytology performance and productivity. *Acta Cytol*, **48**, 17-22.

Schiffman M, Wheeler CM, Castle PE (2002). Atypical Squamous cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study Group. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. *J Infect Dis,* **186**, 1169-72.

Schiller CL, Nickolov AG, Kaul KL, et al (2004). High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization. *Am J Clin Pathol*, **121**, 537-45.

Schorge JO, Lea JS, Elias KJ, et al (2004). P16 as a molecular biomarker of cervical adenocarcinoma. *Am J Obstet Gynecol*, **190**, 668-73.

Schreckenberger C, Kaufmann AM (2004). Vaccination strategies for the treatment and prevention of cervical cancer. *Curr Opin Oncol*, **16**, 485-91.

Sedjo RL, Inserra P, Abrahamsen M, et al (2002). Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. *Cancer Epidemiol Biomarkers Prev*, **11**, 353-9.

Sellors JW, Karwalajtys TL, Kaczorowski J, et al (2003). Incidence, clearance and predictors of human papillomavirus infection in women. *CMAJ*, **168**, 421-5.

Sellors JW, Sankarananyan R (2003). Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginners' Manual. IARC Press, Lyon.

Sgambato A, Zannoni GF, Faraglia B, et al (2004). Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. *Gynecol Oncol*, **92**, 776-83.

Shannon J, Thomas DB, Ray RM, et al (2002). Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. *Cancer Causes Control,* **13**, 691-9.

Shin HR, Lee DH, Herrero R, et al (2003). Prevalence of human papillomavirus infection in women in Busan, South Korea. *Int J Cancer*, **103**, 413-21.

Singh V, Sehgal A, Parashari A, Sodhani P, Satyanarayana L ( 2001). Early detection of cervical cancer through acetic acid application--an aided visual inspection. *Singapore Med J*, **42**, 351-4.

Smith JS, Bosetti C, Munoz N, et al (2004). Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. *Int J Cancer*, **111**, 431-9.

Smith JS, Herrero R, Bosetti C, et al (2002a). Herpes simplex virus-2 as a human papillomavirus co-factor in the etiology of invasive cervical cancer. *J Natl Cancer Inst,* **94**, 1604-13.

Smith JS, Munoz N, Herrero R, et al (2002b). Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *J Infect Dis,* **185**, 324-31.

Snoeck R, Andrei G, De Clercq E (2001). Cidofovir in the treatment of HPV-associated lesions. *Verh K Acad Geneeskd Belg,* **63**, 93-120, discussion 120-2.

Sriamporn S, Swaminathan R, Parkin DM, Kamsa-ard S, Hakama M (2004). Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast Thailand. *Br J Cancer*, **91**, 106-10.

Suh-Burgmann E, Sivret J, Duska LR, Del Carmen M, Seiden MV (2003). Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. *Gynecol Obstet Invest,* **55**, 25-31.

Tajima K, Moore MA (2001). Risk and beneficial factors - fallacy at the individual but not the population level? Relevance to a Practical Prevention Program. *Asian Pacific J Cancer Prev*, **2**, 83-7.

Tanaka H, Sato H, Sato N, et al (2004). Adding HPV16 testing to abnormal cervical smear detection is useful for predicting CIN3: a prospective study. *Acta Obstet Gynecol Scand*, **83**, 497-500.

Tay SK, Tay KJ (2004). Passive cigarette smoking is a risk factor in cervical neoplasia. *Gynecol Oncol*, **93**, 116-20.

Taylor R, Bell J, Coates M, Churches T, Wain G (1996). Cervical cancer in New South Wales women: five-year survival, 1972 to 1991. *Aust N Z J Public Health*, **20**, 413-20.

Thomas DB, Ray RM, Koetsawang A, et al (2001a). Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. *Am J Epidemiol,* **153**, 723-31.

Thomas DB, Ray RM, Kuypers J, et al (2001b). Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers. *Am J Epidemiol*, **153**, 740-8.

Tran-Thanh D, Provencher D, Koushik A, et al (2003). Herpes simplex virus type II is not a cofactor to human papillomavirus in uterine cervix cancer. *Am J Obstet Gynecol,* **188**, 129-34.

Tringler B, Gup CJ, Singh M, et al (2004). Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. *Hum Pathol*, **35**, 689-96.

Türkistanlı EC, Sogukpınar N, Saydam BK, Aydemir G (2003). Cervical cancer prevention and early detection; the role of nurse and midwives. *Asian Pacific J Cancer Prev*, **4**, 39-44.

Unger JB, Ivy JJ, Connor P, et al (2004). Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. *Gynecol Oncol*, **94**, 212-6.

van Duin M, Snijders PJ, Schrijnemakers HF, et al (2002). Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. *Int J Cancer,* **98**, 590-5.

Velema JP, Ferrera A, Figueroa M, et al (2002). Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in Honduras. *Int J Cancer,* **97**, 536-41.

Wang Q (2001). Cancer registration in China. *Asian Pacific J Cancer Prev*, **2** (IACR Suppl), 3-8.

Waterhouse J, Muir C, Shanmugaratnam K, Powell J (Eds) (1982). Cancer Incidence in Five Continents Vol. IV. IARC Scientific Publications No 42. IARC, Lyon.

Wentzensen N, Vinokurova S, von Knebel-Doeberitz M (2004). Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. *Cancer Res*, **64**, 3878-84.

Wesley R, Sankaranarayanan R, Mathew B, et al (1997). Evaluation of visual inspection as a screening test for cervical cancer. *Br J Cancer,* **75**, 436-40.

Waller J, McCaffery KJ, Forrest S, Wardle J (2004). Human papillomavirus and cervical cancer: issues for biobehavioral and psychosocial research. *Ann Behav Med*, **27**, 68-79.

Wu MT, Lee LH, Ho CK, et al (2003). Lifetime exposure to environmental tobacco smoke and cervical intraepithelial neoplasms among nonsmoking Taiwanese women. *Arch Environ Health*, **58**, 353-9.

Yoshida T, Fukuda T, Sano T, et al (2004).Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. *Cancer*, **102**, 100-8.

Zappa M, Visioli CB, Ciatto S, et al (2004). Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. *Br J Cancer*, **90**, 1784-6.

zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. *Nat Rev Cancer,* **2**, 342-50.